Sumanirole

DB06477InvestigationalSmall molecule

Investigated for use/treatment in parkinson's disease.

Mechanism: Parkinson's disease results from degeneration of the dopaminergic cells in the substantia nigra. Several dopamine receptor agonists have been used as antiparkinsonian therapy. Sumanirole is a dopamine receptor agonist with a high selectivity for the D2 receptor subtype over the other closely related D3 and D4 receptor subtypes.
Curator reviewed
Primary indication: Investigated for use/treatment in parkinson's disease.Curator reviewed
Formula / weight: C₁₁H₁₃N₃O · 203.245 g/mol (avg)
Code names: PNU-95666E

Resolves to

Compound

Structure

InChIKeyRKZSNTNMEFVBDT-MRVPVSSYSA-NSMILESCN[C@H]1CN2C(=O)NC3=CC=CC(C1)=C23

Targets

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sumanirole, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.